Article
Clinical Neurology
Ivan Kmezic, Kristin Samuelsson, Anja Finn, Zane Upate, Kaj Blennow, Henrik Zetterberg, Rayomand Press
Summary: This study investigates the diagnostic and prognostic value of axonal injury biomarkers in patients with inflammatory polyneuropathies. The results show higher levels of neurofilament light chain (NfL) and total tau (T-tau) in cerebrospinal fluid (CSF) and plasma of patients with Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and paraproteinemia-related demyelinating polyneuropathy (PDN). NfL levels in CSF and plasma correlate with disability scores in GBS patients. T-tau in plasma is a novel biomarker that could be used for the diagnostic assessment of acute and chronic inflammatory polyneuropathies.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Fei Wu, Weiwei Wang, Yang Yang, Chong Li, Jie Wu, Hanqiu Liu, Yan Ren
Summary: This study explored the value of MR neurography in the diagnosis and differential diagnosis of CIDP. The results showed that CSA and ADC values increased in CIDP patients, while no difference was observed between patients with axonal polyneuropathies and healthy controls. FA decreased in both CIDP and axonal polyneuropathy patients, but there was no difference between the two groups. ROC analysis revealed that FA had better efficiency in diagnosing CIDP, while CSA had better diagnostic accuracy in differentiating CIDP from axonal polyneuropathies.
QUANTITATIVE IMAGING IN MEDICINE AND SURGERY
(2022)
Article
Immunology
Mohammad Taheri, Shayeste Roustapour, Mahdi Gholipour, Bashdar Mahmud Hussen, Solat Eslami, Soudeh Ghafouri-Fard, Arezou Sayad
Summary: Our study compared the expression of four lncRNAs related to regulatory T cells in patients and healthy subjects. The results showed higher expression of three lncRNAs (RMRP, NEST, and FLICR) in patients. However, there was no significant difference in their expressions between acute and chronic inflammatory demyelinating polyneuropathy patients. Gender and disease factors had a significant effect on the expression levels of RMRP and TH2-LCR genes. RMRR performed the best in distinguishing patients from controls.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Mohammad Taheri, Somayeh Sangseifid, Pariya Shahani, Mohammad Mahdi Eftekharian, Shahram Arsang-Jang, Soudeh Ghafouri-Fard
Summary: This study found that the expression levels of SOCS1 and SOCS2 were significantly lower in male CIDP patients compared with controls, with a sex-specific pattern also observed for SOCS3 down-regulation. The diagnostic powers of SOCS1, SOCS2, SOCS3, and SOCS5 genes in the mentioned disorder were 0.61, 0.73, 0.68, and 0.58 respectively. None of the gene expressions were correlated with the age of enrolled cases. The study provides evidence for the involvement of SOCS genes in the pathophysiology of acquired immune-mediated polyneuropathies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Jeffrey A. Allen, Richard A. Lewis
Summary: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic immune-mediated peripheral form of polyneuropathy. Diagnosis of CIDP can be challenging, but clinicians can utilize diagnostic criteria and assessment of treatment response to aid in diagnosis and treatment.
Review
Clinical Neurology
Matthew Silsby, Eva L. Feldman, Richard D. Dortch, Alison Roth, Simon Haroutounian, Yusuf A. Rajabally, Steve Vucic, Michael E. Shy, Anne Louise Oaklander, Neil G. Simon
Summary: Distal sensory polyneuropathy (DSP) is characterized by length-dependent, sensory-predominant symptoms and signs, including chronic pain, tingling, and poor balance. It can be challenging to diagnose and manage. Recent advances in understanding the causes and potential therapies for DSP are discussed in this review.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Review
Clinical Neurology
Pietro Emiliano Doneddu, Marta Dentoni, Eduardo Nobile-Orazio
Summary: In recent years, there has been a heated debate in literature regarding the definition, pathogenetic mechanisms, and diagnostic impact of different variants of CIDP. Recent studies suggest potential different pathological mechanisms in individual variants which could lead to the discovery of specific diagnostic biomarkers and new therapies.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Clinical Neurology
G. Liberatore, F. Manganelli, P. E. Doneddu, D. Cocito, R. Fazio, C. Briani, M. Filosto, L. Benedetti, A. Mazzeo, G. Antonini, G. Cosentino, S. Jann, A. Cortese, G. A. Marfia, A. M. Clerici, G. Siciliano, M. Carpo, M. Luigetti, G. Lauria, T. Rosso, G. Cavaletti, L. Santoro, E. Peci, S. Tronci, M. Ruiz, S. Cotti Piccinelli, A. Schenone, L. Leonardi, A. Toscano, G. Mataluni, E. Spina, L. Gentile, E. Nobile-Orazio
Summary: The study found that in patients with clinical CIDP diagnosis but not meeting EFNS/PNS criteria, multiple abnormal supportive criteria helped to support the diagnosis of CIDP. Increased cerebrospinal fluid proteins and response to immune therapy were the main factors aiding in the diagnosis of CIDP.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Review
Clinical Neurology
Xishun Ma, Lizhen Du, Wenqing Yuan, Tongliang Han
Summary: In recent years, there has been an improved understanding of multiple neuropathy and studies have been conducted on chronic inflammatory neuropathies. Early diagnosis is crucial for treatment and prognosis. High frequency ultrasound has emerged as a promising diagnostic tool for polyneuropathies and has shown progress in its application.
FRONTIERS IN NEUROLOGY
(2022)
Article
Medicine, General & Internal
Dominic O. Co
Summary: Acquired demyelinating syndromes (ADS) are a group of inflammatory demyelinating conditions that include optic neuritis, transverse myelitis, and acute demyelinating encephalomyelitis. Differentiating between subtypes of ADS is important for optimal patient management, and this can be achieved by considering clinical features, laboratory tests (especially autoantibodies), and MRI findings.
MEDICAL CLINICS OF NORTH AMERICA
(2024)
Article
Clinical Neurology
K. Kuitwaard, E. Brusse, B. C. Jacobs, A. F. J. E. Vrancken, F. Eftimov, N. C. Notermans, A. J. van Der Kooi, W. -J. R. Fokkink, D. Nieboer, H. F. Lingsma, I. S. J. Merkies, P. A. van Doorn
Summary: This study found that more frequent lower dosing of IVIg does not improve the efficacy or reduce side effects in stable IVIg-dependent CIDP patients.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Neurosciences
Friederike S. Baehr, Burkhard Gess, Madlaine Mueller, Sandro Romanzetti, Michael Gadermayr, Christiane Kuhl, Sven Nebelung, Joerg B. Schulz, Maike F. Dohrn
Summary: MRI muscle volumetry is a promising method to differentiate and characterize neuropathies in clinical practice, showing significant correlations between muscle volumes and clinical parameters in various neuropathy patients, including those with demyelinating Charcot-Marie-Tooth disease (CMT) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Article
Clinical Neurology
Reza Sadjadi, Stojan Peric, Kelly Gwathmey, Ivo Bozovic, Palibrk Aleksa, Bogdan Bjelica, Ted Burns, Ivana Basta
Summary: The study demonstrated the psychometric stability and construct longitudinal validity of CAPPRI in patients with chronic inflammatory demyelinating polyneuropathy. Strong correlation was found between changes in INCAT scores and CAPPRI scores between visits, with robust CAPPRI effect sizes observed between different PIC categories.
Review
Medicine, General & Internal
Mazyar Shadman
Summary: Chronic lymphocytic leukemia is an immunocompromised blood cancer that can be treated with targeted agents like BTK inhibitors or BCL2 inhibitors, but currently there is no cure for the disease.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Clinical Neurology
Jeffrey A. Allen, Richard A. Lewis
Summary: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic peripheral polyneuropathy that requires managing abnormal immune activity and residual symptoms. Treatment should be adjusted based on individual patient response and there is no reliable disease activity biomarker. Supportive interventions, such as physical therapy, adaptive equipment, pain management, and emotional support, are also crucial.